John Cookson

Summary

Affiliation: East London
Country: UK

Publications

  1. ncbi request reprint Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat
    John Cookson
    Department of Psychiatry, The Royal London Hospital, London, UK
    Int Clin Psychopharmacol 21:267-73. 2006
  2. ncbi request reprint The use of anticonvulsants in the aftermath of mania
    John Cookson
    The Royal London Hospital, St Clement s, London, UK
    J Psychopharmacol 20:23-30. 2006
  3. ncbi request reprint Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study
    John Cookson
    The Department of Psychiatry, Royal London Hospital, London, UK
    Int Clin Psychopharmacol 22:93-100. 2007
  4. doi request reprint Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis
    John Cookson
    Burdett House, Mile End Hospital, London, UK
    J Psychopharmacol 26:42-51. 2012
  5. ncbi request reprint Toward a clinical understanding of bipolar disorders: classification and presentation
    John Cookson
    Royal London Hospital, St Clement s, London, England
    Epilepsia 46:3-7. 2005
  6. ncbi request reprint A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 65:204-10. 2004
  7. ncbi request reprint Managing the aftermath of mania - Newcastle, 2 September 2005: Consensus Meeting Statement
    Allan H Young
    University of Newcastle, Newcastle upon Tyne, UK
    J Psychopharmacol 20:51-4. 2006
  8. ncbi request reprint Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study
    Eduard Vieta
    Bipolar Disorders Program, Hospital Clinic, University of Barcelona IDIBAPS, Barcelona, Spain
    J Affect Disord 106:63-72. 2008
  9. doi request reprint Stability and treatment outcome of distinct classes of mania
    Inge van Rossum
    Medical Department, Eli Lilly Nederland, Grootslag 1 5, Houten, The Netherlands
    Eur Psychiatry 23:360-7. 2008

Detail Information

Publications9

  1. ncbi request reprint Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat
    John Cookson
    Department of Psychiatry, The Royal London Hospital, London, UK
    Int Clin Psychopharmacol 21:267-73. 2006
    ..The NNTs in the elderly were similar. The NNT for several measures of efficacy including remission consistently demonstrated the treatment benefits of duloxetine as well as of fluoxetine and paroxetine compared with placebo...
  2. ncbi request reprint The use of anticonvulsants in the aftermath of mania
    John Cookson
    The Royal London Hospital, St Clement s, London, UK
    J Psychopharmacol 20:23-30. 2006
    ..Valproate continues to be recommended by most current guidelines despite the lack of evidence...
  3. ncbi request reprint Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study
    John Cookson
    The Department of Psychiatry, Royal London Hospital, London, UK
    Int Clin Psychopharmacol 22:93-100. 2007
    ..2%, quetiapine 300 mg/day: 3.9, and placebo: 3.9%). In conclusion, quetiapine compared with placebo significantly reduces time to response and remission compared with placebo, and has a favorable number needed to treat...
  4. doi request reprint Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis
    John Cookson
    Burdett House, Mile End Hospital, London, UK
    J Psychopharmacol 26:42-51. 2012
    ..Younger patients may be more susceptible to hyperprolactinaemia. Trial reports often fail to state the frequency of raised levels...
  5. ncbi request reprint Toward a clinical understanding of bipolar disorders: classification and presentation
    John Cookson
    Royal London Hospital, St Clement s, London, England
    Epilepsia 46:3-7. 2005
    ..The development of new diagnostic trends and their clinical implications are discussed...
  6. ncbi request reprint A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 65:204-10. 2004
    ..Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study. We describe the results of a 52-week, open-label continuation of that trial...
  7. ncbi request reprint Managing the aftermath of mania - Newcastle, 2 September 2005: Consensus Meeting Statement
    Allan H Young
    University of Newcastle, Newcastle upon Tyne, UK
    J Psychopharmacol 20:51-4. 2006
  8. ncbi request reprint Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study
    Eduard Vieta
    Bipolar Disorders Program, Hospital Clinic, University of Barcelona IDIBAPS, Barcelona, Spain
    J Affect Disord 106:63-72. 2008
    ....
  9. doi request reprint Stability and treatment outcome of distinct classes of mania
    Inge van Rossum
    Medical Department, Eli Lilly Nederland, Grootslag 1 5, Houten, The Netherlands
    Eur Psychiatry 23:360-7. 2008
    ..Differential treatment course and outcome after 12 weeks of treatment were examined for three distinct classes of patients with acute mania in bipolar disorder...